Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.295 AUD | +3.19% | +2.37% | +28.86% |
May. 02 | Boral to Exit S&P/ASX 200 Index Following Takeover Bid | MT |
Mar. 25 | Miners, healthcare firms push Australia stocks higher | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.4 for the 2025 fiscal year.
- The company has a low valuation given the cash flows generated by its activity.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- With an expected P/E ratio at 30.83 and 25.9 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+28.86% | 1.34B | B- | ||
+14.23% | 69.5B | C+ | ||
+7.11% | 8.2B | B | ||
-20.55% | 7.97B | B- | ||
-4.06% | 7.84B | C | ||
+2.26% | 4.66B | B- | ||
+17.12% | 4.32B | B+ | ||
+1.41% | 4.19B | B- | ||
-3.02% | 3.89B | B | ||
+21.42% | 3.62B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SIG Stock
- Ratings Sigma Healthcare Limited